Amerigen Pharmaceuticals Revenue and Competitors

Lyndhurst, NJ USA

Location

$35M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Amerigen Pharmaceuticals's estimated annual revenue is currently $2.7M per year.(i)
  • Amerigen Pharmaceuticals received $35.0M in venture funding in January 2015.
  • Amerigen Pharmaceuticals's estimated revenue per employee is $100,500
  • Amerigen Pharmaceuticals's total funding is $35M.

Employee Data

  • Amerigen Pharmaceuticals has 27 Employees.(i)
  • Amerigen Pharmaceuticals grew their employee count by 0% last year.

Amerigen Pharmaceuticals's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Amerigen Pharmaceuticals?

Amerigen is a privately held company that was founded in 2007. Our company's focus is the development, manufacture and sale of high quality generic pharmaceutical products for two of the most important markets in the worldthe USA and China. Our US office is located in Lyndhurst, NJ and houses staff involved in executive management, product and business development, finance, regulatory affairs, and commercial operations. Product development is being undertaken at various locations around the world under the supervision of its experienced R&D, quality, and regulatory leaders. Our main facility is in China and located in Suzhou, Jiangsu Providence, near Shanghai. The Suzhou facility houses executive and local management for the Chinese market and is also a US FDA and Chinese CFDA approved finished dose manufacturing site. We currently have an active portfolio of products under development, filed or intended for filing as ANDA's with the FDA. These are in addition to the product who's approval confirmed the FDA's satisfactory GMP inspection of the Suzhou facility in 2010. We also have nine products approved for sale in China and are pursuing opportunities to bring additional products to the Chinese market. Utilizing our western systems of management, quality assurance and control, along with our manufacturing site approvals from the FDA and CFDA, Amerigen is uniquely positioned to introduce high quality and affordable medicines into both the American and Chinese markets.

keywords:Healthcare,Pharmaceuticals

$35M

Total Funding

27

Number of Employees

$2.7M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Amerigen Pharmaceuticals News

2022-04-17 - Primary Mediastinal Large B-cell Lymphoma Treatment ...

Baxter, Hikma Pharmaceuticals PLC, Cipla Inc, Amneal Pharmaceuticals LLC, Pfizer Inc, STI PHARMA, LLC, Amerigen Pharmaceuticals Limited,...

2022-04-17 - Microscopic Polyangiitis Market Future Growth Explored in ...

... Teijin Pharma Limited, Amerigen Pharmaceuticals Limited, Sandoz International GmbH, and TTY Biopharm Company. New product launches and...

2022-04-17 - Paraganglioma Treatment Market, Future Trend Scenario ...

Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator ... Amneal Pharmaceuticals LLC, Amerigen Pharmaceuticals Limited,...

2019-09-03 - Transverse Myelitis Treatment Market to Witness Widespread ...

... Teva Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., ... Aurobindo Pharma, Baxter, Amerigen Pharmaceuticals Limited, and ...

2019-09-03 - Excellent Growth of Lead Poisoning Treatment Market ...

Some of the Prominent Players of Global Lead Poisoning Treatment Market are: Akorn, Incorporated, Amerigen Pharmaceuticals Limited, Teva ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M270%N/A
#2
$2.9M288%N/A
#3
$5.9M307%N/A
#4
$8M313%N/A
#5
$8.1M31N/AN/A

Amerigen Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2015-01-12$35.0MUndisclosedFosun PharmaArticle